Healthcare products company West Pharmaceutical Services (NYSE: WST) will be reporting earnings this Thursday morning. Here’s what to look for.

West Pharmaceutical Services beat analysts’ revenue expectations by 5.6% last quarter, reporting revenues of $766.5 million, up 9.2% year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ revenue estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting West Pharmaceutical Services’s revenue to grow 5.5% year on year to $787.7 million, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.69 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services has missed Wall Street’s revenue estimates three times over the last two years.

Looking at West Pharmaceutical Services’s peers in the life sciences tools & services segment, only Danaher has reported results so far. It beat analysts’ revenue estimates by 0.6%, delivering year-on-year sales growth of 4.4%.

There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 5.3% on average over the last month. West Pharmaceutical Services is up 11.8% during the same time and is heading into earnings with an average analyst price target of $319.25 (compared to the current share price of $282).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.